An interventional study of Sealing Device in Pancreatectomy and Hepatic Resection, sponsored by Polyganics BV. Completed at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.
Sponsored by Polyganics BV · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Polyganics BV (Groningen, The Netherlands), in close collaboration with University Hospital-Eppendorf (UKE) Hamburg, has developed the Sealing Device for use in hepato-pancreato-bilary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site. The Sealing Device has been challenged in pre-clinical testing (laboratory and in-vivo work), but has not been evaluated for safety and performance in humans.
This investigation will be conducted to clinically assess the safety and performance of Sealing Device as a means to reduce bile and pancreatic juice leakage in hepato-pancreato-bilary (HPB) surgery. Secondarily, the control of minimal to moderate bleeding will be assessed. To achieve adequate representation of the primary objective, the study will contain two separate surgical patient groups: Liver and Pancreas.
The primary objective of the study is to demonstrate safety and performance in reducing intra- and post-operative leakage (bile and pancreatic juices) by using the Sealing Device in patients undergoing elective hepatic resection or distal pancreatectomy.
The study will be conducted as an open-label, single-arm, multicenter study with a 16 months follow up. Up to 80 patients (40 liver and 40 pancreas patients) will be enrolled at up to 7 sites in Europe.
Polyganics BV is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Preoperative inclusion criteria:
Subjects will be eligible according the following criteria:
During the surgery, the patients also need to comply with the intraoperative criteria.
Intraoperative inclusion criteria:
Subjects will be eligible according the following criteria:
Exclusion Criteria:
Preoperative exclusion criteria
Subjects who meet any of the following criteria will be excluded from participation:
Intraoperative exclusion criteria:
Subjects who meet any of the following criteria will be excluded from participation:
Total surgery requiring > 3 HPB Sealing Devices of 10 x 5 cm (which equals a resection surface of more than 88cm2).
Additional for liver group:
Subjects with liver cirrhosis Grade C on the Child-Turcotte-Pugh score.
Additional for pancreas group:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sealing Device applied in hepatic resection or distal pancreatectomy
Device: Sealing Device
The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
Bile leakage
Incidence of post-operative bile leakage (International Study Group of Liver Surgery Bile leakage Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C
Time frame: 30 days
Pancreatic leakage
Incidence of post-operative pancreatic juice leakage (International Study Group of Pancreas Surgery Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C
Time frame: 30 days
Bleeding
Intra-operative control bleeding
Time frame: Day 1
Leak-associated comorbidities
Incidence of leak-associated comorbidities
Time frame: 16 months
re-intervention
Incidence of re-intervention
Time frame: 16 months
Ease of Use
Ease of Use of the device as measured by questionnaire
Time frame: Day 1
Post-operative bile leakage
Incidence of post-operative bile leakage (liver only)
Time frame: 90 and 180 days
Post-hepatectomy haemorrhage (PHH)
Incidence of post-operative bleeding (liver only)
Time frame: 30 days
Post-operative pancreatic juice leakage
Incidence of post-operative pancreatic juice leakage (pancreas only)
Time frame: 90 and 180 days
Post-pancreatectomy haemorrhage (PPH)
Incidence of post-operative bleeding (pancreas only)
Time frame: 30 days
(Serious) Adverse Device Effects
Incidence of (Serious) Adverse Device Effects
Time frame: 16 months
Incidence of transfusion
Incidence of transfusion
Time frame: 16 months
Length of hospital stay
Length of hospital stay
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2020 to primary completion in Nov 2021, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polyganics BV